LATE PLEISTOCENE-HOLOCENE ENVIRONMENTAL AND CLIMATIC CHANGES IN THE BAIKAL REGION INFERRED FROM MULTI-PROXY LACUSTRINE RECORDS

18-2

LATE PLEISTOCENE-HOLOCENE ENVIRONMENTAL AND CLIMATIC CHANGES IN THE BAIKAL REGION INFERRED FROM MULTI-PROXY LACUSTRINE RECORDS

18-2

Room-temperature lasing in microring cavities with an InAs/InGaAs quantum-dot active region

Microring cavities (diameter D = 2.7-7 μm) with an active region based on InAs/InGaAs quantum dots are fabricated and their characteristics are studied by the microphotoluminescence method and near-field optical microscopy. A value of 22 000 is obtained for the Q factor of a microring cavity with the diameter D = 6 μm. Lasing up to room temperature is obtained in an optically pumped ring microlaser with a diameter of D = 2.7 μm. © 2013 Pleiades Publishing, Ltd

Investigation of the effect of surface passivation on microdisk lasers based on InGaAsN/GaAs quantum well active region

Microdisk lasers based on three InGaAsN/GaAs quantum wells with different types of surface passivation are fabricated and studied under optical pumping. Room temperature lasing at 1.3 μm in 7 μm in diameter microdisks with InGaAsN/GaAs QW is demonstrated. We evaluated the thermal resistance as 1 °C/mW.publishedVersionPeer reviewe

Investigation of the efficacy and safety of a diindolylmethane-based drug in patients with cervical intraepithelial neoplasia grades 1-2 (CIN 1-2)

Objective. To investigate the efficacy and safety of the vaginal suppositories Cervicon-DIM (diindolylmethane) in patients with histologically confirmed neoplastic processes of the cervix uteri - cervical intraepithelial neoplasia grades 1-2 (CIN 1-2). Subject and methods. The randomized study enrolled 160 patients aged 18 to 45 years; the follow-up period was 3 months. The investigators analyzed clinical and laboratory data and evaluated the efficacy and safety of treatment with Cervicon-DIM versus placebo. Results. Cervicon-DIM was shown to contribute to the elimination of human papillomavirus infection and to the regression of mild and moderate neoplastic processes of the cervix uteri (CIN 1-2). Conclusion. It is appropriate to prescribe Cervicon-DIM as one suppository (100 mg) twice daily for 3 months to patients with human papillomavirus infection and those with CIN 1-2. © 2018, Bionika Media Ltd. All rights reserved